



## Mvasi™ (bevacizumab-awwb) – First-time biosimilar launch

- On July 19, 2019, [Allergan and Amgen announced](#) the launch of [Mvasi \(bevacizumab-awwb\)](#), a biosimilar to Genentech's [Avastin \(bevacizumab\)](#).
  - [Zirabev™ \(bevacizumab-bvzr\)](#), Pfizer's biosimilar to Avastin was also FDA approved on June 28, 2019. Pfizer's launch plans for Zirabev are pending.
- Mvasi and Avastin share the following indications:
  - Metastatic colorectal cancer (MCC), in combination with intravenous [fluorouracil](#)-based chemotherapy for first- or second-line treatment
  - MCC, in combination with fluoropyrimidine-[irinotecan](#)-or fluoropyrimidine-[oxaliplatin](#)-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen
  - Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with [carboplatin](#) and [paclitaxel](#) for first-line treatment
  - Recurrent glioblastoma in adults
  - Metastatic renal cell carcinoma in combination with [interferon alfa](#)
  - Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and [cisplatin](#) or paclitaxel and [topotecan](#).
- In addition, Avastin is indicated for epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- The wholesale acquisition cost (WAC) of Mvasi is \$677.40 per 100 mg and \$2,709.60 per 400 mg single-dose vial. This is 15% lower than the WAC for Avastin.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.